Biologic therapies and bone loss in rheumatoid arthritis

详细信息    查看全文

• 作者：C. A. F. Zerbini ; P. Clark ; L. Mendez-Sanchez…
• 关键词：Antirheumatic agents ; Bone fractures ; Monoclonal antibodies ; Osteoporosis ; Rheumatic diseases
• 刊名：Osteoporosis International
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：28
• 期：2
• 页码：429-446
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Orthopedics; Endocrinology; Rheumatology;
• 出版者：Springer London
• ISSN：1433-2965
• 卷排序：28

文摘

IntroductionRheumatoid arthritis (RA) is a common systemic autoimmune disease of unknown cause, characterized by a chronic, symmetric, and progressive inflammatory polyarthritis. One of the most deleterious effects induced by the chronic inflammation of RA is bone loss. During the last 15 years, the better knowledge of the cytokine network involved in RA allowed the development of potent inhibitors of the inflammatory process classified as biological DMARDs. These new drugs are very effective in the inhibition of inflammation, but there are only few studies regarding their role in bone protection. The principal aim of this review was to show the evidence of the principal biologic therapies and bone loss in RA, focusing on their effects on bone mineral density, bone turnover markers, and fragility fractures.